Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma
Member News
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company ...
Related or similar articles
November 2, 2018
Life Sciences Co-Working Incubator Labshares Launches in Newton
A new office and laboratory incubator for emerging biotechnology and life science companies has just opened in Newton’s Charles River Mill District.
Labshares News
November 14, 2018
Science incubator Labshares Newton is Set to Expand
The next groundbreaking medical discovery could be made right here in the city, as companies conduct research and experiments at Labshares Newton, an “incubator lab” on Bridge Street that is in the process of expanding.
Labshares News
April 28, 2020
Labshares Newton Awards Free Project-Based Lab Space to Three Innovative Diagnostics Companies Conducting COVID-19 Research
Labshares Newton, a shared office and laboratory incubator for emerging biotechnology and life science companies, today announced that it has selected three startup companies developing COVID-19 diagnostics to receive free lab space. The companies...
Labshares News